Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
Detection of inflammation and glial cell-related biomarkers in adults with spinal muscular atrophy receiving nusinersen therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arslan Doruk, Ergul-Ulger Zeynep, Goksen Sibel, Inan Berin, Esendagli Gunes, Erdem-Ozdamar Sevim, Tan Ersin, Bekircan-Kurt Can Ebru
Аннотация
INTRODUCTION: Pathogenesis of spinal muscular atrophy (SMA) is not limited to motor neuron degeneration and many different cells and tissue types, especially glial cells and neuroinflammation, are thought to play a role in the process. We aimed to define the contribution of glial cell and neuroinflammation-related molecules to the SMA process and to identify biomarkers that may be diagnostic and/or predict the clinical response to nusinersen treatment.
METHODS: Twenty-four adult SMA patients receiving nusinersen treatment and twelve healthy subjects were included. Four molecules associated with glial cells (GFAP and GDNF) and neuroinflammatory activity (YKL-40 and IL-6) were analyzed.
RESULTS: SMA patients had higher cerebrospinal fluid (CSF) GFAP and IL-6 levels (p < 0.05) and lower GDNF levels (p < 0.05) compared to the controls. CSF levels of IL-6 and YKL-40 decreased and GDNF increased under nusinersen treatment (p < 0.05). Higher baseline CSF GFAP levels were associated with more favorable clinical responses to treatment.
DISCUSSION: GFAP is a marker of both diagnostic and prognostic importance for SMA disease, and higher levels are associated with better clinical outcome. New therapies targeting glial cells and anti-inflammatory agents may have a positive impact on the clinical utility of current treatments.
METHODS: Twenty-four adult SMA patients receiving nusinersen treatment and twelve healthy subjects were included. Four molecules associated with glial cells (GFAP and GDNF) and neuroinflammatory activity (YKL-40 and IL-6) were analyzed.
RESULTS: SMA patients had higher cerebrospinal fluid (CSF) GFAP and IL-6 levels (p < 0.05) and lower GDNF levels (p < 0.05) compared to the controls. CSF levels of IL-6 and YKL-40 decreased and GDNF increased under nusinersen treatment (p < 0.05). Higher baseline CSF GFAP levels were associated with more favorable clinical responses to treatment.
DISCUSSION: GFAP is a marker of both diagnostic and prognostic importance for SMA disease, and higher levels are associated with better clinical outcome. New therapies targeting glial cells and anti-inflammatory agents may have a positive impact on the clinical utility of current treatments.